99 related articles for article (PubMed ID: 21955928)
21. Three-Dimensional Volume Imaging to Increase the Accuracy of Surgical Management in a Case of Recurrent Chordoma of the Clivus.
Gomes JPP; Veloso JRC; Altemani AMAM; Chone CT; Altemani JMC; de Freitas CF; Lima CSP; Braz-Silva PH; Costa ALF
Am J Case Rep; 2018 Oct; 19():1168-1174. PubMed ID: 30275439
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
Wang L; Wu Z; Tian K; Wang K; Li D; Ma J; Jia G; Zhang L; Zhang J
J Neurosurg; 2017 Dec; 127(6):1257-1267. PubMed ID: 28059654
[TBL] [Abstract][Full Text] [Related]
23. Metastatic clival chordoma: a case report of multiple extraneural metastases following resection and proton beam radiotherapy in a 5-year old boy.
Rutkowski MJ; Birk HS; Wood MD; Perry A; Nicolaides T; Ames CP; Gupta N
J Neurosurg Pediatr; 2017 May; 19(5):531-537. PubMed ID: 28304223
[TBL] [Abstract][Full Text] [Related]
24. Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression.
Schönegger K; Gelpi E; Prayer D; Dieckmann K; Matula C; Hassler M; Hainfellner JA; Marosi C
Anticancer Drugs; 2005 Nov; 16(10):1139-43. PubMed ID: 16222158
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab as salvage therapy for progressive brain stem gliomas.
Reithmeier T; Lopez WO; Spehl TS; Nguyen T; Mader I; Nikkhah G; Pinsker MO
Clin Neurol Neurosurg; 2013 Feb; 115(2):165-9. PubMed ID: 22652237
[TBL] [Abstract][Full Text] [Related]
26. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
Stacchiotti S; Morosi C; Lo Vullo S; Casale A; Palassini E; Frezza AM; Dinoi G; Messina A; Gronchi A; Cavalleri A; Venturelli E; Morelli D; Pilotti S; Collini P; Brich S; Tamborini E; Mariani L; Casali PG
Cancer; 2018 Oct; 124(20):4056-4063. PubMed ID: 30216418
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Jackman DM; Kindler HL; Yeap BY; Fidias P; Salgia R; Lucca J; Morse LK; Ostler PA; Johnson BE; Jänne PA
Cancer; 2008 Aug; 113(4):808-14. PubMed ID: 18543326
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
[TBL] [Abstract][Full Text] [Related]
30. [Chordoma: diagnostic considerations and review of the literature].
Conforti R; Sardaro A; Tecame M; Rossi C; Vargas O; Raucci A; Sica A
Recenti Prog Med; 2013; 104(7-8):322-7. PubMed ID: 24042401
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Bukowski RM; Kabbinavar FF; Figlin RA; Flaherty K; Srinivas S; Vaishampayan U; Drabkin HA; Dutcher J; Ryba S; Xia Q; Scappaticci FA; McDermott D
J Clin Oncol; 2007 Oct; 25(29):4536-41. PubMed ID: 17876014
[TBL] [Abstract][Full Text] [Related]
32. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
33. MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):13. PubMed ID: 24852397
[No Abstract] [Full Text] [Related]
34. Chordoma: a case series and review of the literature.
Alan O; Akin Telli T; Ercelep O; Tanrikulu Simsek E; Basoglu Tuylu T; Mutis A; Hasanov R; Kaya S; Akgül Babacan N; Dane F; Yumuk PF
J Med Case Rep; 2018 Aug; 12(1):239. PubMed ID: 30145982
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib and bevacizumab have synergistic activity against melanoma.
Schicher N; Paulitschke V; Swoboda A; Kunstfeld R; Loewe R; Pilarski P; Pehamberger H; Hoeller C
Clin Cancer Res; 2009 May; 15(10):3495-502. PubMed ID: 19447871
[TBL] [Abstract][Full Text] [Related]
36. Chondroid chordoma of the lateral skull base.
Rossiello R; Ferrara G; Varricchio A; Baldi A; Motta S; Motta G
ORL J Otorhinolaryngol Relat Spec; 2001; 63(2):114-8. PubMed ID: 11244373
[TBL] [Abstract][Full Text] [Related]
37. Clival chordoma: a single-centre outcome analysis.
Jägersberg M; El Rahal A; Dammann P; Merkler D; Weber DC; Schaller K
Acta Neurochir (Wien); 2017 Oct; 159(10):1815-1823. PubMed ID: 28478512
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.
Riggs H; Jalal SI; Baghdadi TA; Bhatia S; McClean J; Johnson C; Yu M; Taber D; Harb W; Hanna N
Clin Lung Cancer; 2013 May; 14(3):224-9. PubMed ID: 23102811
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
40. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
